Updates from Biogen
Biogen pioneers innovative science to deliver transformative medicines for neurology, immunology, and rare diseases.
- New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026 (Achievement · November 16, 2026)
Biogen shared five-year data from the Clarity AD study long-term extension, showing the long-term effects of lecanemab in patients. The results were presented at the Clinical Trials on Alzheimer’s…